KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Notes Payables (2020 - 2024)

Recursion Pharmaceuticals' Notes Payables history spans 5 years, with the latest figure at $55000.0 for Q1 2024.

  • For Q1 2024, Notes Payables fell 91.68% year-over-year to $55000.0; the TTM value through Mar 2024 reached $55000.0, down 91.68%, while the annual FY2023 figure was $41000.0, 57.73% down from the prior year.
  • Notes Payables reached $55000.0 in Q1 2024 per RXRX's latest filing, up from $41000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.1 million in Q2 2021 to a low of $41000.0 in Q4 2023.
  • Average Notes Payables over 5 years is $645428.6, with a median of $96000.0 recorded in 2022.
  • Peak YoY movement for Notes Payables: plummeted 97.03% in 2022, then surged 631.58% in 2023.
  • A 5-year view of Notes Payables shows it stood at $1.1 million in 2020, then crashed by 91.61% to $90000.0 in 2021, then rose by 7.78% to $97000.0 in 2022, then crashed by 57.73% to $41000.0 in 2023, then surged by 34.15% to $55000.0 in 2024.
  • Per Business Quant, the three most recent readings for RXRX's Notes Payables are $55000.0 (Q1 2024), $41000.0 (Q4 2023), and $695000.0 (Q3 2023).